table of contents hologic , inc . notes to consolidated financial statements ( continued ) ( in thousands , except per share data ) the acquisition also provides for up to two annual earn-out payments not to exceed $ 15000 in the aggregate based on biolucent 2019s achievement of certain revenue targets . the company considered the provision of eitf 95-8 , and concluded that this contingent consideration represents additional purchase price . as a result , goodwill will be increased by the amount of the additional consideration , if any , as it is earned . as of september 26 , 2009 , the company has not recorded any amounts for these potential earn-outs . the allocation of the purchase price was based upon estimates of the fair value of assets acquired and liabilities assumed as of september 18 , 2007 . the components and allocation of the purchase price consisted of the following approximate amounts: .

Table:
net tangible assets acquired as of september 18 2007 | $ 2800
developed technology and know how | 12300
customer relationship | 17000
trade name | 2800
deferred income tax liabilities net | -9500 ( 9500 )
goodwill | 47800
final purchase price | $ 73200
as part of the purchase price allocation , all intangible assets that were a part of the acquisition were identified and valued .
it was determined that only customer relationship , trade name and developed technology had separately identifiable values .
the fair value of these intangible assets was determined through the application of the income approach .
customer relationship represented a large customer base that was expected to purchase the disposable mammopad product on a regular basis .
trade name represented the biolucent product name that the company intended to continue to use .
developed technology represented currently marketable purchased products that the company continues to sell as well as utilize to enhance and incorporate into the company 2019s existing products .
the deferred income tax liability relates to the tax effect of acquired identifiable intangible assets and fair value adjustments to acquired inventory , as such amounts are not deductible for tax purposes , partially offset by acquired net operating loss carryforwards of approximately $ 2400 .
4 .
sale of gestiva on january 16 , 2008 , the company entered into a definitive agreement pursuant to which it agreed to sell full u.s .
and world-wide rights to gestiva to k-v pharmaceutical company upon approval of the pending gestiva new drug application ( the 201cgestiva nda 201d ) by the fda for a purchase price of $ 82000 .
the company received $ 9500 of the purchase price in fiscal 2008 , and the balance is due upon final approval of the gestiva nda by the fda on or before february 19 , 2010 and the production of a quantity of gestiva suitable to enable the commercial launch of the product .
either party has the right to terminate the agreement if fda approval is not obtained by february 19 , 2010 .
the company agreed to continue its efforts to obtain fda approval of the nda for gestiva as part of this arrangement .
all costs incurred in these efforts will be reimbursed by k-v pharmaceutical and are being recorded as a credit against research and development expenses .
during fiscal 2009 and 2008 , these reimbursed costs were not material .
the company recorded the $ 9500 as a deferred gain within current liabilities in the consolidated balance sheet .
the company expects that the gain will be recognized upon the closing of the transaction following final fda approval of the gestiva nda or if the agreement is terminated .
the company cannot assure that it will be able to obtain the requisite fda approval , that the transaction will be completed or that it will receive the balance of the purchase price .
moreover , if k-v pharmaceutical terminates the agreement as a result of a breach by the company of a material representation , warranty , covenant or agreement , the company will be required to return the funds previously received as well as expenses reimbursed by k-v .
source : hologic inc , 10-k , november 24 , 2009 powered by morningstar ae document research 2120 the information contained herein may not be copied , adapted or distributed and is not warranted to be accurate , complete or timely .
the user assumes all risks for any damages or losses arising from any use of this information , except to the extent such damages or losses cannot be limited or excluded by applicable law .
past financial performance is no guarantee of future results. .

Question: what portion of the final purchase price is related to developed technology?
Answer: 16.8%
Calculation: divide(12300, 73200)